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Brian G. Hockley,a Megan N. Stewart,b Phillip Sherman,a Carole Quesada,a
Michael R. Kilbourn,a Roger L. Albin,c,d and Peter J. H. Scotta,b*()-[18F]Flubatine was selected for clinical imaging of α4β2 nicotinic acetylcholine receptors because of its high afﬁnity and
appropriate kinetic proﬁle. A fully automated synthesis of ()-[18F]ﬂubatine as a sterile isotonic solution suitable for clinical
use is reported, as well as the ﬁrst evaluation in nonhuman primates (rhesus macaques). ()-[18F]Flubatine was prepared by
ﬂuorination of the Boc-protected trimethylammonium iodide precursor with [18F]ﬂuoride in an automated synthesis module.
Subsequent deprotection of the Boc group with 1-M HCl yielded ()-[18F]ﬂubatine, which was puriﬁed by semi-preparative
HPLC. ()-[18F]Flubatine was prepared in 25% radiochemical yield (formulated for clinical use at end of synthesis, n=3), >95%
radiochemical purity, and speciﬁc activity=4647Ci/mmol (171.9GBq/μmol). Doses met all quality control criteria conﬁrming
their suitability for clinical use. Evaluation of ()-[18F]ﬂubatine in rhesus macaques was performed with a Concorde MicroPET
P4 scanner (Concorde MicroSystems, Knoxville, TN). The brain was imaged for 90min, and data were reconstructed using the
3-D maximum a posteriori algorithm. Image analysis revealed higher uptake and slower washout in the thalamus than those
in other areas of the brain and peak uptake at 45min. Injection of 2.5μg/kg of nifene at 60min initiated a slow washout of
[18F]ﬂubatine, with about 25% clearance from the thalamus by the end of imaging at 90min.
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59Introduction
Dysfunction of the cholinergic neurotransmitter system is one factor
contributing to cognitive decline in neurodegenerative disorders
such as Alzheimer’s disease.1 Reﬂecting this, noninvasive positron
emission tomography imaging of cholinergic brain function is an
extremely active research arena. Radiopharmaceuticals that permit
measurement of the vesicular acetylcholine transporter,
acetylcholinesterase activity, and both muscarinic and nicotinic
acetylcholine receptors (nAChRs) ﬁnd widespread clinical
application (for recent reviews, see Refs 2–72–7). We currently
evaluate acetylcholinesterase activity by using 1-[11C]
methylpiperidin-4-yl propionate8 and the vesicular acetylcholine
transporter with (2R,3R)-5-[18F]ﬂuoroethoxy-benzovesamicol.9 With
the goal of expanding our understanding of cholinergic dysfunction
in our clinical population, we were desirous of also making a
radiopharmaceutical available for clinical imaging of nAChRs. Many
radiopharmaceuticals for quantiﬁcation of nAChRs have been
reported to date (reviewed in Refs 2–72–7), but we focused our
attention on [18F]A8538010–13 and [18F]ﬂubatine ([18F]NCFHEB)14–18
as they have been used to image nAChRs in a clinical setting.
Ultimately, [18F]ﬂubatine, a radiolabeled derivative of epibatidine,
was selected because it has the most practical kinetic proﬁle (the
slow kinetics of [18F]A85380 severely limit its utility for imaging
cognitively impaired patients4,5,10).J. Label Compd. Radiopharm 2013, 56 595–599Herein, we report a fully automated radiosynthesis of ()-[18F]
ﬂubatine that provides the radiopharmaceutical formulated as a
sterile, isotonic solution suitable for clinical use. The original
syntheses provided (+)-[18F]ﬂubatine and ()-[18F]ﬂubatine in 2%
radiochemical yield and utilized an ethyl carbamate-protected
bromo precursor, specialized microwave synthesis equipment,
iodotrimethylsilane-mediated carbamate deprotection, and two
semi-preparative HPLC puriﬁcations including a chiral one as a
racemic precursorwas employed.14–16 Thiswas not readily adaptable
to clinical radiopharmaceutical production in our positron-emission
tomography (PET) center, and so, we have built upon this initial workCopyright © 2013 John Wiley & Sons, Ltd,
f
f.
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596and capitalized on the enantiomerically pure Boc-protected trialkyl
ammonium iodide precursor now commercially available to
simplify the synthesis. We report a fully automated, high yielding
radiosynthesis of ()-[18F]ﬂubatine on a standard automated
ﬂuorine-18 synthesis module. Acid-mediated deprotection of the
Boc group and puriﬁcation of the product by using semi-
preparative HPLC with a standard C18 column make it suitable
for production of clinical doses. Completion of this synthesis
optimization in our laboratory coincided with reports of an
extensive precursor evaluation study by Fischer and colleagues,19
which reported improved yields (up to 60% by using manual
radiochemical methods although no radioactivity amounts were
speciﬁed) and also concluded that the Boc-protected trialkyl
ammonium iodide is the precursor of choice for synthesizing
()-[18F]ﬂubatine. Finally, with the goal of expanding the repository
of imaging data and the understanding of how ()-[18F]ﬂubatine
behaves in different species, we also report the ﬁrst evaluation
of ()-[18F]ﬂubatine in nonhuman primates (rhesus macaques).Materials and methods
General considerations
Unless otherwise stated, reagents and solvents were commercially
available and used without further puriﬁcation: ()-ﬂubatine
precursor and reference standard were purchased from ABX
Advanced Biochemicals; potassium carbonate, sodium hydroxide,
and hydrochloric acid were purchased from Sigma Aldrich;
kryptoﬁx-2.2.2, acetonitrile, and dimethyl sulfoxide (DMSO) were
purchased from Acros Organics; ethanol for HPLC was purchased
from Decon Laboratories, Inc.; and sodium chloride, 0.9% United
States Pharmacopeia (USP), and sodium phosphates for injection,
USP, were purchased from Hospira. Other synthesis components
were obtained as follows: sterile ﬁlters were obtained fromMillipore,
sterile product vials were purchased from Hollister-Stier, and
QMA-Light Sep-paks were purchased from Waters Corporation.
Sep-Paks were ﬂushed prior to use: 10mL of NaHCO3—10mL of
deionized water—10-mL ethanol—10mL of deionized water.Figure 1. Typical semi-preparative HPLC trace. UV, ultraviolet; AU, absorbance unit.
www.jlcr.org Copyright © 2013 JohSynthesis of ()-[18F]ﬂubatine
To prepare ()-[18F]ﬂubatine, we conﬁgured a General Electric
TRACERlab FXFN synthesis module as previously described
20
and loaded as follows: Vial 1, potassium carbonate (3.5mg) in
deionized water (0.5mL); Vial 2, kryptoﬁx-2.2.2 (10–15mg) in
acetonitrile (1mL); Vial 3, ()-ﬂubatine precursor (1mg) in DMSO
(0.6mL); Vial 4, 1-M HCl (1mL); Vial 5, 0.5-M NaOH (2mL); product
collection vial, 0.9% sodium chloride for injection (USP, 3.9mL)
and sodium phosphates for injection (USP, 0.1mL).
[18F]Fluoride (~800mCi and 29.6 GBq) was produced via the
18O(p,n)18F nuclear reaction by using a General Electric PETtrace
cyclotron equipped with a high-yield ﬂuorine-18 target. The [18F]
ﬂuoride was delivered in a 1.5-mL bolus of [18O]H2O to the
synthesis module and trapped on a QMA-Light Sep-Pak to
remove [18O]H2O. [
18F]Fluoride was then eluted into the reaction
vessel by using aqueous potassium carbonate (3.5mg in 0.5mL
of water). The solution of kryptoﬁx-2.2.2 (10–15mg in 1mL of
acetonitrile) was then added to the reaction vessel, and the
[18F]ﬂuoride was dried by evaporating the water–acetonitrile
azeotrope. Evaporation of the azeotrope was achieved by
heating the reaction vessel to 80°C and drawing full vacuum
for 4min. After this time, the reaction vessel was cooled to 60°C
and subjected to both an argon stream and a vacuum draw
simultaneously for another 4min. The solution of ()ﬂubatine
precursor (1mg) in DMSO (600μL) was added to the dried [18F]
ﬂuoride, and the reaction was heated to 120°C with stirring for
10min. Subsequently, the reaction mixture was cooled to 80°C,
followed by the addition of 1-M HCl (1mL) and then maintained
at 80°C with stirring for an additional 5min to remove the Boc
group. The reaction mixture was then cooled to 50°C, quenched
with 0.5-M NaOH, and puriﬁed by semi-preparative HPLC
(column, Phenomonex Luna C18(2) 10μ, 250 × 10mm; mobile
phase, 4% ethanol in 20-mM NaH2PO4; pH, 4.0; ﬂow rate,
4mL/min; and typical semi-preparative trace, Figure 1). The
product peak (tR 20–25min) was collected into the product
collection vial with concomitant dilution into 0.9% sodium chloride
for injection, USP, and sodium phosphates for injection, USP. The
ﬁnal formulation was then passed through a 0.22-μm ﬁlter into an Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2013, 56 595–599
B. G. Hockley et al.sterile dose vial and submitted for quality control testing as
outlined later in the text. Typical radiochemical yields of
formulated ()-[18F]ﬂubatine prepared using this method are
25% at end of synthesis (EOS).Quality control of ()-[18F]ﬂubatine
Quality control testing of ()-[18F]ﬂubatine was conducted using
the guidelines outlined in the US Pharmacopeia using the standard
tests previously described,20 and results are reported in Table 1.
Testing included visual inspection, pH, chemical purity and
radiochemical purity (RCP, see Analysis of Chemical Purity and
Radiochemical Purity/Identity section), speciﬁc activity, residualTable 1. Quality control data for ()-[18F]ﬂubatine (mean values
Visual
inspection pH
t1/2
(min)
RCP
(%)
SA
(Ci/mmol)
RSA
Pass 6.5 110 99.8 4647
RCP, radiochemical purity; SA, speciﬁc activity; RSA MeCN–DMSO
Figure 2. Typical analytical HPLC trace. UV, ultraviolet. RAD, radioactivity detector.
Copyright © 2013 JohJ. Label Compd. Radiopharm 2013, 56 595–599solvent analysis, residual kryptoﬁx analysis, sterile ﬁlter integrity,
bacterial endotoxin analysis, and sterility testing.
Analysis of chemical purity and radiochemical purity/identity
Chemical and radiochemical purities/identities are analyzed
using a Shimadzu LC2010 HPLC equipped with a radioactivity
detector and an ultraviolet (UV) detector, and a representative
analytical HPLC trace is shown (Figure 2). Radiochemical purity
for doses must be >95%, and identity is conﬁrmed by
comparing the retention time of the radiolabeled product with
that of the corresponding unlabeled reference standard.
Column—Phenomonex Synergi Polar-RP 4μ, 150 × 4.6mm;
mobile phase—50% acetonitrile : 50% 0.1-M acetic acid; pH, 4.5;reported, n= 3)
MeCN-
DMSO
K222
(μg/mL)
Bubble
point
Endotoxins
(EU/mL) Sterility
Pass <50 Pass <2.0 Pass
, Residual Solvent Analysis acetonitrile–dimethyl sulfoxide.
www.jlcr.orgn Wiley & Sons, Ltd.
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598ﬂow rate, 1.0mL/min; oven—40°C; UV, 254nm; tR = 5.0min; and
capacity factor = 2.56. ()-[19F]Flubatine nonradioactive reference
standard was purchased from ABX Advanced Biochemicals.Primate micropositron-emission tomography imaging
All animal studies were performed in accordance with the
standards set by the University Committee on Use and Care of
Animals (UCUCA) at the University of Michigan. Primate imaging
studies (n= 3) were performed using a mature female rhesus
monkey (weight = 5.8 kg). The monkey was anesthetized
(isoﬂurane), intubated, and positioned in a Concorde MicroPET
P4 scanner. Following a transmission scan was the injection
of the animal intravenously with ()-[18F]ﬂubatine (4–5mCi
(148–185MBq)) as a bolus over 1min. The collection of emission
data was started with radiotracer injection, and the brain was
imaged for 90min (18 × 5-min frames). Image data were
reconstructed using the 3-D maximum a posteriori algorithm
(Figure 3). By using a summed image, regions of interest were
drawn over sections of the brain (thalamus, cortex, striatum,
and cerebellum), and time–radioactivity curves were calculated
(Figure 4). For the displacement study, a 2.5-μg/kg dose of the
selective α4β2 nAChR agonist nifene was injected intravenously
at 60min after the radiotracer injection, and scanning continued
until 90min, and time–radioactivity curves were generated in an
analogous fashion (Figure 5).Results and discussion
Synthesis of ()-[18F]ﬂubatine
The original syntheses of ()-[18F]ﬂubatine reported in the
literature utilized a racemic ethyl carbamate-protected bromo
precursor that was reacted with [18F]ﬂuoride in a microwave
system, and the protecting group was removed by treating with
iodotrimethylsilane. Final puriﬁcation by semi-preparative HPLC
involved an initial chiral column to separate enantiomers and then
a secondHPLC to remove chemical impurities andprovide ()-[18F]
ﬂubatine in 2% yield.14,16 This chemistry has proven suitable for the
initial preclinical evaluation of the radiopharmaceutical14,15 and the
ﬁrst-in-man evaluation that has been recently reported.17,18
However, as we looked to make ()-[18F]ﬂubatine available to our
clinicians, we had cause to develop an entirely new synthesis more
suitable for our synthesis equipment, by using the newly
commercially available enantiomerically pure Boc-protected
trimethylammonium salt precursor.Figure 3. Typical summed primate microPET images acquired with ()-[18F]ﬂubatin
and received a 90-min dynamic PET scan (18 × 5-min frames). Image data were recon
and C, sagittal).
www.jlcr.org Copyright © 2013 Joh()-[18F]Flubatine was prepared according to Scheme 1, and
as outlined in Synthesis of (–)-[18F]Flubatine section. Subjecting
the Boc-protected trimethylammonium iodide precursor to our
standard ﬂuorination conditions resulted in high conversion
(>95%) to Boc-protected ()-[18F]ﬂubatine. As we wished to
avoid using iodotrimethylsilane in our clinical synthesis modules,
alternative strategies for removing the carbamate protecting
group were evaluated. Aqueous hydrochloric acid (1M) is our
standard protocol for removal of Boc-protecting groups in
ﬂuorine-18 radiochemical reactions, and gratifyingly it worked
well in this case too. Similar results were reported by Fischer
and co-workers in their precursor matrix study.19 A single semi-
preparative HPLC yielded ()-[18F]ﬂubatine, and the total
synthesis time was about 60min. Three consecutive syntheses
were completed to qualify the synthetic method for clinical
production of ()-[18F]ﬂubatine, with typical yields of formulated
product of 200mCi (7.4 GBq) at EOS (25% based upon 800mCi
(29.6 GBq) of [18F]ﬂuoride, non-decay corrected, n=3). The
radiochemical purity was >95%, and speciﬁc activity was
4647 Ci/mmol (171.9 GBq/μmol) at EOS. Doses of ()-[18F]
ﬂubatine met all of the established release criteria as
summarized in Table 1 and described earlier, conﬁrming their
suitability for use in clinical PET imaging of nAChRs.
Micropositron-emission tomography imaging
in rhesus monkeys
With doses of ()-[18F]ﬂubatine available, we were interested in
assessing the regional distribution and time–activity curves in
the rhesus macaque brain. Following a transmission scan, the
administration of the monkey, with 4–5mCi (148–185MBq) of
()-[18F]ﬂubatine, was performed, and it received a 90-min
dynamic PET scan (18×5-min frames). Image data were
reconstructed using the 3-D maximum a posteriori algorithm,
and expected uptake in the thalamus, frontal cortex, and striatum,
areas of the brain rich in α4β2 nAChRs, was apparent (Figure 3).
By using a summed image, regions of interest were drawn
over sections of the brain (thalamus, cortex, striatum, and
cerebellum), and time–radioactivity curves were calculated.
Uptake was normalized to injected dose and averaged for the
three scans (Figure 4). Higher uptake and slower washout of
()-[18F]ﬂubatine were observed in the thalamus than those in
the other regions of the brain, which was expected and is
consistent with previously reported data in piglets14,15 and
humans.17,18 Peak uptake for the thalamus in the rhesus
monkeys (45min) was found to be faster than the reported peak
uptake for piglets (80min). Although no obvious explanatione. The monkey was administered with 4–5mCi (148–185MBq) of ()-[18F]ﬂubatine
structed using the 3-D maximum a posteriori algorithm (A, transverse; B, coronal;
n Wiley & Sons, Ltd. J. Label Compd. Radiopharm 2013, 56 595–599
Figure 4. Brain tissue time–radioactivity curves (uptake normalized to injected
dose and averaged for three scans). Data are mean ± standard error.
Figure 5. Brain tissue time–radioactivity curves for displacement experiment with
unlabeled nifene (2.5μg/kg, intravenous, uptake normalized to injected dose,
n= 1).
Scheme 1. Synthesis of ()-[18F]ﬂubatine. DMSO, dimethyl sulfoxide.
B. G. Hockley et al.exists for this species difference, it does lend support to the
recent suggestion that ()-[18F]ﬂubatine kinetics will allow
all kinetic parameters to be estimated from clinical PET
data acquired over only 90min.17,18 Finally, the injection of a
2.5-μg/kg dose of the selective α4β2 nAChR agonist nifene
21 at
60min initiated a slow washout of [18F]ﬂubatine from the
thalamus, with about 25% clearance by the end of the imaging
study at 90min (Figure 5).
Conclusion
In conclusion, a fully automated radiosynthesis of ()-[18F]
ﬂubatine has been established. Doses met all quality control
criteria, conﬁrming their suitability for application in clinical
imaging. Evaluation of ()-[18F]ﬂubatine in rhesus macaques
revealed higher uptake and slower washout in the thalamus thanCopyright © 2013 JohJ. Label Compd. Radiopharm 2013, 56 595–599those in the other areas of the brain, and the time–activity curves
conﬁrm that ()-[18F]ﬂubatine has kinetics that will simplify PET
imaging of α4β2 nAChRs in a clinical setting.Acknowledgements
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